Last reviewed · How we verify
Alexza Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
1 Phase 3
3 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Inhaled loxapine 10 mg | Inhaled loxapine 10 mg | marketed | ||||
| Placebo IM | Placebo IM | marketed | ||||
| Inhaled Loxapine | Inhaled Loxapine | phase 3 | Atypical antipsychotic | Dopamine D2 receptor, Serotonin 5-HT2A receptor | Psychiatry |
Therapeutic area mix
- Neurology · 1
- Psychiatry · 1
- Respiratory · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Eli Lilly and Company · 2 shared drug classes
- Acacia Pharma Ltd · 1 shared drug class
- AstraZeneca · 1 shared drug class
- All India Institute of Medical Sciences, Bhubaneswar · 1 shared drug class
- Alza Corporation, DE, USA · 1 shared drug class
- Assistance Publique Hopitaux De Marseille · 1 shared drug class
- Alkermes, Inc. · 1 shared drug class
- AbbVie · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Alexza Pharmaceuticals, Inc.:
- Alexza Pharmaceuticals, Inc. pipeline updates — RSS
- Alexza Pharmaceuticals, Inc. pipeline updates — Atom
- Alexza Pharmaceuticals, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Alexza Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/alexza-pharmaceuticals-inc. Accessed 2026-05-16.